open access

Vol 4, No 1 (2008)
Review paper
Published online: 2008-02-28
Get Citation

The role of antiangiogenic agents in multidrug cancer therapy

Stanisław Szala
Onkol. Prak. Klin 2008;4(1):1-7.

open access

Vol 4, No 1 (2008)
REVIEW ARTICLES
Published online: 2008-02-28

Abstract

Several data indicate that a solid neoplastic tumor cannot grow beyond certain dimensions without developing its own network of blood and lymphatic vessels. Thus, inhibition of vascularization causes death of cancer cells. Such observations have led to novel cancer therapeutic approach called antiangiogenic strategy. This strategy relies mainly on using vascular-endothelial growth factor (VEGF) inhibitors, as well as inhibitors blocking activity of its receptors (VEGFR-1, 2, 3), i.e. the primary factors and receptors taking part in angio-and lymphangiogenesis. Preclininical studies and clinical trials have demonstrated that antiangiogenic therapeutic approach might become an essential component of multidrug cancer therapy capable of targeting both neoplastic cells and endothelial cells of cancerous blood vessels. The paper discusses advantages of multidrug therapy approach, as well as its inherent drawbacks.

Abstract

Several data indicate that a solid neoplastic tumor cannot grow beyond certain dimensions without developing its own network of blood and lymphatic vessels. Thus, inhibition of vascularization causes death of cancer cells. Such observations have led to novel cancer therapeutic approach called antiangiogenic strategy. This strategy relies mainly on using vascular-endothelial growth factor (VEGF) inhibitors, as well as inhibitors blocking activity of its receptors (VEGFR-1, 2, 3), i.e. the primary factors and receptors taking part in angio-and lymphangiogenesis. Preclininical studies and clinical trials have demonstrated that antiangiogenic therapeutic approach might become an essential component of multidrug cancer therapy capable of targeting both neoplastic cells and endothelial cells of cancerous blood vessels. The paper discusses advantages of multidrug therapy approach, as well as its inherent drawbacks.
Get Citation

Keywords

antiangiogenic drugs; multidrug therapy

About this article
Title

The role of antiangiogenic agents in multidrug cancer therapy

Journal

Oncology in Clinical Practice

Issue

Vol 4, No 1 (2008)

Article type

Review paper

Pages

1-7

Published online

2008-02-28

Bibliographic record

Onkol. Prak. Klin 2008;4(1):1-7.

Keywords

antiangiogenic drugs
multidrug therapy

Authors

Stanisław Szala

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl